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Mohd-Hafifi Jamal1, Wei-Choong Ch’ng1, Khatijah Yusoff1,2 and Norazizah Shafee1,2*Abstract
Background: Cisplatin resistance is a serious problem in cancer treatment. To overcome it, alternative approaches
including virotherapy are being pursued. One of the candidates for anticancer virotherapy is the Newcastle disease
virus (NDV). Even though NDV's oncolytic properties in various cancer cells have been widely reported, information
regarding its effects on cisplatin resistant cancer cells is still limited. Therefore, we tested the oncolytic efficacy of a
strain of NDV, designated as AF2240, in a cisplatin-resistant breast cancer cell line.
Methods: Cisplatin-resistant cell line (MCF7-CR) was developed from the MCF7 human breast adenocarcinoma cell
line by performing a seven-cyclic exposure to cisplatin. Following NDV infection, fluorescence-activated cell sorting
(FACS) analysis and immunoblotting were used to measure cell viability and viral protein expression, respectively.
Production of virus progeny was then assessed by using the plaque assay technique.
Results: Infection of a mass population of the MCF7-CR with NDV resulted in 50% killing in the first 12 hours
post-infection (hpi), comparable to the parental MCF7. From 12 hpi onwards, the remaining MCF7-CR became less
susceptible to NDV killing. This reduced susceptibility led to increased viral protein synthesis and virus progeny
production. The reduction was also associated with a prolonged cell survival via stabilization of the survivin protein.
Conclusions: Our findings showed for the first time, the involvement of survivin in the reduction of NDV-induced
oncolysis in a subpopulation of cisplatin-resistant cells. This information will be important towards improving the
efficacy of NDV as an anticancer agent in drug resistant cancers.
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Cisplatin [cis-diaminedichloroplatinum(II), CDDP] is one
of the widely used drugs to treat cancer patients. It was
first discovered in 1969 [1] and has since been used to
treat a variety of malignant tumors such as lung, ovarian,
head and neck, bladder and testicular cancers [2]. Even
though CDDP and other platinum complexes are not
commonly used in the current therapy of breast cancers,
they have recently been introduced into the clinical
setting as an emerging new treatment modality [3,4]. The
mode of action of this drug is believed to result from
binding of its platinum molecule onto DNA of target cell.* Correspondence: nshafee@biotech.upm.edu.my
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reproduction in any medium, provided the orThe incorporation of CDDP into DNA produces intras-
trand and interstrand crosslink adducts [5,6]. The DNA-
platinum adducts then prevent cells from undergoing
DNA replication, prevent efficient RNA transcription
and disrupting cell cycle which eventually lead them to
apoptosis [7,8].
Survivin is usually found at low level in normal cells but
it is highly expressed in most tumors [9]. High survivin
expressions in cancer cells correlated to poor prognosis,
decreased apoptosis, and increased resistance to CDDP
[10,11]. As a bifunctional protein, survivin, like other mem-
bers of inhibitor of apoptosis proteins (IAPs), suppresses
apoptosis by binding to caspase-3, 7 and 9 [12]. Besides
that, previous reports suggested that survivin played major
roles in cell division where it was dominantly induced
during G2/M phase to assist mitosis and cytokinesis [13].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and





















Figure 1 Morphology and viability of MCF7 and MCF7-CR cells
in the presence of cisplatin: (A) Surviving MCF7 cells following
cisplatin treatment showed an enlarged morphology (right panel),
compared to the untreated cells (left panel). They were also found
to attach stronger to flask surfaces (right panel). Magnification: 200×.
(B) MCF7 cells that survived the seven-cyclic exposure to cisplatin
were maintained for another 30 days in drug-free media prior to the
infection experiment. The morphology of these MCF7-CR cells
reverted back to the morphology of the parental MCF7.
Magnification: 100×. (C) An increased IC50 was observed in the
MCF7-CR compared to the MCF7 cells.
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been explored to overcome the drug resistance problems,
and virotherapy has emerged as a promising approach.
The idea of employing virus in cancer treatment arose in
the early 1960s. Since then, several groups of DNA and
RNA viruses with oncolytic properties have been identi-
fied including Newcastle Disease Virus (NDV). NDV was
first discovered in Newcastle upon Tyne in 1927 and it
causes a highly contagious disease affecting birds and
poultry [14]. The use of NDV in treating cancer was first
reported by Cassel and Garret in 1965 [15] and since
then, the interest in using NDV as anti-neoplastic treat-
ment has expanded steadily. NDV strain AF2240 was first
isolated in the 1960s from a field outbreak in Malaysia
and it was reported to cause high mortality and morbility
in poultry. A study done by Othman et al. [16] showed
that NDV strain AF2240 has the ability to infect MCF7
cell line resulting in apoptosis. However, the activity of
NDV AF2240 on cisplatin-resistant MCF7 cell line has
not been reported. Thus, in this study, we investigated
the oncolytic effect of this NDV strain on cisplatin-
resistant MCF7 cancer cells.
Results
Cisplatin (CDDP) resistance correlates with morphological
changes in MCF7 cells
MCF7 cell line was employed as a model to study NDV
oncolytic activity in CDDP-sensitive versus CDDP-
resistant breast cancer cells. During the CDDP treat-
ment, surviving MCF7 cells showed an average of 2-fold
increase in size compared to the control untreated
MCF7 (Figure 1A). There was no change in the DNA
content of the enlarged cells (data not shown). During
trypsinization, it took a longer time for them to be dis-
lodged suggesting a stronger attachment to flask sur-
faces. During the 30-day maintenance in drug-free
media, the surviving cells' morphology reverted back to
almost similar to the parental MCF7 (Figure 1B, right
panel). Prior to infection experiments, their level of re-
sistance to CDDP was determined using the MTT assay.
The resulting IC50 for both MCF7 and MCF7-CR was
found to be 130.7 μM and 163.4 μM, respectively
(Figure 1B). The newly established MCF7-CR showed
25% increase in resistance towards CDDP compared to
the parental MCF-7. The resistant factor of MCF7-CR
was calculated as 1.3.
Reduced NDV-induced cytotoxicity in a subpopulation of
MCF7-CR cells
To investigate the effects of NDV-AF2240 cytotoxicity on
MCF7 and MCF7-CR, the cells were infected with the virus
at 1.0 MOI and subjected to a flowcytometric analysis at 4
different (12, 24, 48 and 96) hpi. Mock-infected cells were
used as controls. For both cell lines, percent viabilityappeared to decrease over time (Figure 2). Even though the
MCF7-CR is more resistant to CDDP than its parental
MCF-7, these cells are still susceptible to NDV oncolysis. A
particularly drastic decrease in cell viability was observed
during the first 12 hpi, followed by a gradual decrease for
the rest of the infection period. At 24 hpi, more viable cells
were observed in the infected MCF7-CR compared to the
MCF7. Higher viability of MCF7-CR than MCF7 was main-
tained until the end of the experiment. From 12 hpi to 24
hpi, percent viability in infected MCF7-CR did not change
suggesting a degree of cellular resistancy towards NDV



















Figure 2 Cell viability in the mock- and NDV-infected MCF7 and
MCF7-CR cells. Cytometric analysis of the cells was performed at
12, 24, 48 and 96 hours post-infection and viable cell populations
were quantitated. The values were represented in a line graph for
ease of analysis. Results are representatives of a triplicate
experiments.
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To examine whether the different pattern of cell death
observed in the infected MCF7 versus MCF7-CR cells
also affected NDV viral protein synthesis, total cell
lysates were then subjected to SDS-PAGE and immuno-
blotting analyses. Mock-infected cells were used as
controls. At 0 hpi, no viral protein was detected on the
membrane for both the MCF7 and MCF7-CR samples
(Figure 3A). After 12 hpi, several bands representing
different viral proteins were observed on the membrane.
This observation suggested that NDV protein synthesis
occurred at high efficiency within the first 12 hours of
infection. As the infection time progressed, the intensity
of virus protein bands started to differ between the
MCF7 and MCF7-CR.
As our objective was to study how well NDV can infect
cisplatin-resistant breast cancer cells, we used cisplatin sen-
sitive MCF7 as the benchmark. Based on the protein band
intensity at 12 hpi, the MCF7-CR appeared to contain more
viral proteins than MCF7 (Figure 3A). To confirm this ob-
servation, we probed the samples with a monoclonal
antibody against the nucleocapsid protein (NP) of NDV.
The NP protein is the most abundant protein in the virus
which makes it easier to detect and analyse [17]. To investi-
gate quantitative difference between the band intensities,
the NP blot was analyzed using the ImageJ software and
the intensity values were normalized against the β-actin
loading control. The plotted values showed that the amount
of the NP protein inside MCF7 is lower compared to
MCF7-CR and their intensity differences started to increase
as time progressed (Figure 3B). These results suggest that
in the infected MCF7-CR, NDV protein synthesis occurred
at higher level compared to the parental MCF7 cells.High level NDV progeny production in infected MCF7-CR
We have shown that NDV protein level was higher in
the infected MCF7-CR compared to MCF7. To test
whether this increase in viral protein correlates with an
increase in viral progeny production, we performed a
plaque assay using culture media obtained from the
infected cells at 12, 24, 48 and 96 hpi. At all the time
points tested, virus yield in the MCF7-CR were always
higher than MCF7 (Figure 4). However, the difference
was statistically significant only at 24, 48 and 96 hpi.
This increase was in line with the amount of viral
protein detected in the cells (Figure 3). It is interesting
to note that at 24 hpi, virus yield in MCF7-CR was
markedly increased compared to the other samples. This
sudden jump in virus production correlated with
reduced NDV-induced oncolysis (Figure 2B) and
increased viral protein level (Figure 3B).
Enhanced NDV production in MCF7-CR is associated with
survivin stabilization
Survivin, a member of the IAP family, is highly
expressed in most cancers. It has been shown to be
upregulated during virus infection to assist virus produc-
tion [18,19]. To test whether survivin level is affected by
NDV infection particularly in MCF7-CR, we performed
immunoblot studies on all the infected and mock-
infected MCF7 and MCF7-CR samples. Since survivin
upregulation is known to be a factor in cisplatin resist-
ance [10,20,21], we used CDDP as a positive control in
this study. Exposure of MCF7-CR but not MCF7 led to
increased survivin level in the cells (data not shown).
These results confirmed that our MCF7-CR responded
the same way to CDDP as other previously reported
cisplatin-resistant MCF7 cell lines (22). When MCF7-CR
and MCF7 cells were infected with NDV, their survivin
levels increased beginning immediately after the adsorp-
tion period (considered as 0 hpi in this study;
Figure 5A). In certain viral infections, survivin expres-
sion was increased and it is shown to be involved in fa-
cilitating virus production [22]. At later time points after
the infection, the level of survivin began to decrease.
When the survivin bands were quantitated and plotted,
a dramatic decrease was noted at 24 hpi in MCF7 com-
pared to its level at 12 hpi (Figure 5B). In MCF7-CR on
the other hand, the survivin level, despite being lower
than MCF7, was retained. Hence, there is no significant
change in MCF7-CR survivin level from 12 to 24 hpi.
This retention of survivin level in MCF7-CR may con-
tribute towards the reduced cell death (Figure 2) and
increased virus production (Figure 4) at 24 hpi.
Discussion
Cisplatin is one of the most potent and widely employed
drugs in cancer treatment. However, development of
Figure 3 Detection of NDV viral proteins in the mock- and NDV-infected MCF7 and MCF7-CR cells. (A) Polyclonal antibodies against NDV
were used to probe for viral proteins in the total cell lysates harvested following different hours post-infection. A monoclonal antibody against
the NP protein of NDV was also used. (B) The intensity of the NP protein bands were quantitated and plotted in a graphical format. Values are
presented as means ± SD of triplicate blots.
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considerable advances in this field, the mechanism of re-
sistance development and maintenance is still not fully
understood. Alternative therapies including the use of
oncolytic viruses are being studied. Recently, it was
shown that a local isolate of NDV, AF2240, was able to
induce high level of apoptosis in several cancer cell lines
[23,24]. To investigate whether this virus is also oncolytic
in cisplatin-resistant cancer cells, we studied its infectivity
in MCF7 cell line versus cisplatin-resistant MCF7-CR.
To investigate the oncolytic effects of NDV-AF2240 on
cisplatin-resistant cancer cells, we generated our own sub-
cell line from breast cancer cell, MCF7. Repeated exposure
of cisplatin to MCF7 resulted in a generation of a 1.3-fold
increased in CDDP-resistance sub-cell line, MCF7-CR.
This cell line displayed similar morphological changes to
other cisplatin-resistant MCF7 cells [25]. Similar to these
findings, our MCF7-CR also showed higher nucleus to
cytoplasm ratio, and they attached stronger to flask sur-
faces. Following NDV infection, these cells were found to
be susceptible to NDV oncolytic activity. This finding is in
agreement with recent reports which showed an inductionof apoptosis in chemoresistant cancer cells [26,27] using
NDV-HUJ and NDV-FMW strains, respectively.
In this study, we showed that NDV AF2240 killed al-
most 50% of both MCF7 and MCF7-CR cell lines during
the first 12 hpi. From this time point onwards, the
infected MCF7 cells continued to show an exponential
reduction in viability suggesting their continued suscep-
tibility to NDV-induced killing. The MCF7-CR, however,
showed no significant reduction in their viability begin-
ning from 12 until 24 hpi. The cells which were killed
during the first 12 hpi in both MCF7 and MCF7-CR per-
haps represent a 'rapidly cycling' pool of cells [28]. It
was shown that rapidly proliferating cells were more sus-
ceptible to vesicular stomatitis virus (VSV)-induced
oncolysis [29]. In the present study, the drastic reduction
in cell viability in both infected MCF7 and MCF7-CR
after 12 hpi was strongly suggestive of the involvement
of cell cycle phases in the infectivity and cytotoxicity of
NDV. Virus internalization was previously shown to be
affected by these phases [30]. In addition, cisplatin resist-
ance caused changes in cell cycle regulatory proteins
which affect their way of responding to the drug [31].
Figure 4 Plaque assay analysis using the NDV-infected MCF7
and MCF7-CR cell culture media. At 12, 24, 48 and 96 hours
post-infection, 100 μl of the infected cell culture media were
removed and subjected to the plaque assay as described in
Methods section. The resulting plaques were calculated and a graph
was plotted. Values are presented as means ± SD of triplicate
experiments. *p< 0.05.
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MCF7-CR to respond differently to NDV infection as well.
Even though this has to be examined further, especially in
the context of chemoresistant cancer cells, our results
showed that certain subpopulations of CDDP-resistant
cells have different degrees of susceptibility to NDV.
After 12 hpi, the surviving cells in MCF7-CR became
more resistant towards NDV killing compared to MCF7.
When we measured the level of viral proteins inside the
cells, we found that this reduced cytotocixity in MCF7-
CR after 12 hpi was associated with increased NDV pro-
tein level in the cells. Viruses are known to interfere
with cell cycle regulation in order to subvert host-cell
function to favor viral protein translation [26]. Even
though development of cisplatin-resistance is multifac-
torial [7,10], these changes will undoubtedly affect the
way cells respond to viral infection. One of the proposed
mechanisms of cisplatin resistance development involved
apoptosis inhibitor proteins (IAPs) such as survivin.
Survivin expression is known to be influenced by viruses
to cause cell cycle aberration in infected cells in order to
increase viral protein expression [32,33]. Its expression
was also increased during viral infections to facilitate
virus production [22]. In this study we showed that a
reduced susceptibility of MCF7-CR to NDV cytotoxicity
after 12 hpi was associated with a stabilization of survi-
vin in the cells. As the infection progressed, the survivin
level became reduced which directly correlated with
reduced cell viability.
The mechanism as to how NDV regulates survivin is
still not completely understood. Nonetheless Zhu et al.,
showed that upregulation of survivin during virusinfection led to a prolonged cell viability which may
assist virus production [18]. In the present study, the
stabilization of survivin in MCF7-CR beginning from 12
hpi might have led to their prolonged survival which
allowed for increased viral protein production and viral
progeny secretion. In hepatitis-B virus infection, a viral
protein was shown to interact with host protein com-
plex, affecting caspase activation in a survivin-dependent
manner [19]. We observed that stabilization of survivin
in MCF7-CR beginning at 12 hpi was associated with an
intracellular accumulation of NDV proteins. This con-
comitant event may have implications in the observed
cellular responses to NDV infection after 12 hpi. Based
on this observation, it is tempting to speculate the in-
volvement of viral protein(s) in the stabilization of survi-
vin, reduction of NDV-induced cell killing and increase
viral progeny secretion. We are currently investigating
this possibility.
Cisplatin resistant cells have been shown to express
higher survivin than their cisplatin-sensitive parents
[34]. The increase in survivin rendered them less suscep-
tible to apoptosis. These inherent properties of cisplatin-
resistant cells may make them more susceptible to NDV
AF2240 infectivity and viral replication. NDV-LaSota
strain was shown to be more susceptible to apoptosis-
resistant cells [35]. In addition, NDV-HUJ was also
shown to be more infectious towards cancer cells
expressing the livin protein, which is another family
member of the IAPs [26]. Therefore it is likely that the
increase in the intracellular viral protein and virus pro-
geny production in MCF7-CR at 24 hpi was associated
with stabilization of survivin level in the cells beginning
at 12 hpi. This suggests that survivin in one of the main
protein involved in the infectivity and oncolytic activity
of NDV. Taken together, our findings suggest that survi-
vin can be a potential target molecule to improve the
efficacy of NDV as anti-cancer agents.
Conclusion
Resistance to CDDP is a major problem in the effective
management of cancers including metastatic breast can-
cers. One of the alternative approaches to address this
problem is the use of oncolytic viruses. In this study, we
showed that MCF7-CR cells are susceptible to NDV in-
fection. A subpopulation of these cells became less sus-
ceptible to NDV killing after 12 hours of infection. The
reduced susceptibility was associated with a stabilization
of survivin which led to a prolonged cell survival leading
to increased viral protein synthesis and progeny produc-
tion. The reduced susceptibility of only a subpopulation
of MCF7-CR cells after 12 hpi also suggests a possible
relationship between NDV infection and cell cycle
phases. We are currently pursuing an investigation into
this relationship. Nonetheless, our findings in the
Figure 5 Survivin protein levels in the mock- and NDV-infected MCF7 and MCF7-CR cells at different hpi. (A) Survivin protein expression
in total cell lysates were detected using a monoclonal antibody against the protein. (B) Intensities of the resulting survivin band were
quantitated, normalized to the β-actin control and the values were plotted as means ± SD of readings from triplicate blots. *p< 0.05, **p< 0.01.
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oncolytic effects of NDV in CDDP-resistant cells. This
information will be useful in the design of therapeutic
approaches using NDV as an anticancer agent in
chemoresistant cancers.
Methods
Establishment of cisplatin-resistant MCF-7 cell line
Estrogen-dependent MCF7 cells were obtained from the
ATCC (HTB-22) and maintained in DMEM media sup-
plemented with 10% fetal bovine serum and 1% anti-
biotic/antimycotic. The media, serum and antibiotic/
antimycotic was purchased from PAA Laboratories:
Pasching, Austria. A humidified atmosphere of 37°C and
5% CO2 was provided for cell growth. Cisplatin-resistant
MCF-7 (MCF7-CR) was established from the surviving
population of the parental MCF7 breast cancer cells
(ATCC) following a cisplatin treatment. The treatment
was performed as a seven-cyclic 24 h exposure to a final
concentration of 50 mM cisplatin (Sigma-Aldrich: St.
Louis, MO). Following the treatment, surviving cells
were maintained for another 30 days in drug-free media.
MCF-7 and MCF-7 CR cells were routinely tested for
the presence of Mycoplasma to avoid contamination.
Assessment of in vitro cisplatin resistancy
Cells were plated in triplicates into 96-well tissue culture
plates at a concentration of 1 × 104 cells per well in
200 μl of culture media. Cisplatin was added at a finalconcentration in the range of 0 – 200 μM 24 h post-
plating and the cells were incubated for 24 h in 5% CO2
at 37°C. 200 μl of MTT reagent (Sigma Aldrich: St.
Louis, MO; final concentration of 0.5 mg/ml in DMEM)
was added to each well for 4 h incubation at 37°C, fol-
lowed by addition of 100 μl of DMSO (Sigma Aldrich:
St. Louis, MO). Absorbance was read at an excitation
wavelength of 595 nm on an ELISA microplate reader
(Model 550; BioRAD: Philadelphia, PA). Cell survival
was measured as a percentage of surviving cell over un-
treated control cells. For both cell lines the concentra-
tion of cisplatin which resulted in 50% growth inhibition
(IC50) was determined.
NDV infection of sensitive and resistant MCF-7 cell
cultures
Exponentially growing MCF-7 and MCF-7 CR cells were
seeded in T-75 flasks at a concentration of 3 × 106 cells
per flask. The cells were then infected with NDV at 1
multiplicity of infection (MOI). After 1 h, virus-containing
medium was removed and fresh growth medium was
introduced into each flask. The cell culture was incubated
at 37°C and 5% CO2 and harvested at different time
points. Uninfected cells were used as controls.
Harvesting of cells and Immunoblot analysis
Cell pellets were harvested by lysis in 1× RIPA buffer
(Pierce Biotechnology: Rockford, IL) containing prote-
ase inhibitor cocktail (Roche Diagnostics: Mannheim,
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Assay kit (Pierce Biotechnology: Rockford, IL). Equal
amount of protein samples were added to 6× sodium
dodecyl sulfate loading buffer (1 μl loading buffer: 5 μl
protein sample). The sample mixtures were boiled for
5 min before being resolved by sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS-PAGE) to
separate the proteins on the basis of their molecular
weights. After electrophoresis, the proteins were trans-
ferred to a polyvinylidene fluoride (PVDF) transfer
membrane by electroblotting, and probed for survivin
and NDV proteins using an anti-survivin rabbit mAb
(Cell Signaling Technology: Danvers, MA), anti-actin
(Sigma Aldrich: St. Louis, MO), anti-NDV and anti-
NP. The blot was developed and individual bands were
quantitated and normalized to the β-actin control
using the ImageJ software (Wayne Rasband, NIH:
Bethesda, MD).
Plaque assay
A monolayer of SW620 cells was prepared in wells of a
6-well plate. 10-fold dilutions of virus stock were pre-
pared and 1 ml aliquots were inoculated onto the cell
monolayers. The plate was incubated at 37°C and 5%
CO2 for 1 h. After the incubation period, the monolayers
were covered with a nutrient medium containing agar
and the plate was incubated for 6 days. The monolayers
were fixed with 1% formaldehyde in 0.15 N NaCl and
stained with neutral red for overnight. The plate was
washed and dried for plaque observation.
Statistical analysis
Statistical analyses were performed using the GraphPad
Prism 5 (GraphPad Software, Inc., La Jolla, CA). Student's
t-test was used to evaluate the significance of differences
between experimental groups. Statistically-significant dif-
ferences were defined as p values less than 0.05.Abbreviations
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